Literature DB >> 1989665

Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.

M C Bibby1, R M Phillips, J A Double, G Pratesi.   

Abstract

Flavone acetic acid (FAA) is a synthetic flavonoid with dramatic pre-clinical anti-tumour activity involving a vascular component in its mechanism but no clinical effects have been seen to date. As FAA also has immunomodulatory activity, immunological factors might explain differences in activity between mouse and man. This study examines the influence of host immune status on the anti-tumour activity of FAA. Two human colon tumour xenografts (COBA, HT-29) fail to respond to FAA in nude mice. The lack of activity of FAA against HT-29 xenografts cannot be explained on the basis of limited drug bioavailability as achievable plasma, and tumour levels of FAA are similar to those seen in sensitive murine colon tumours. The immune status of the host also influences the activity of FAA against two transplantable tumours of the mouse colon. Both these tumours are highly responsive to FAA in their normal NMRI hosts, but neither tumours exhibited significant growth delay in thymectomised NMRI or nude hosts. Histological examination of treated tumours revealed significant areas of haemorrhagic necrosis in all three hosts. These data suggest a clear immunological component in the mechanism of action of FAA which is separate from the previously described haemorrhagic necrosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989665      PMCID: PMC1971643          DOI: 10.1038/bjc.1991.12

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action.

Authors:  S Hill; K B Williams; J Denekamp
Journal:  Eur J Cancer Clin Oncol       Date:  1989-10

2.  In vitro chemosensitivity testing of flavone acetic acid (LM975; NSC 347512) and its diethylaminoethyl ester derivative (LM985; NSC 293015).

Authors:  W A Schroyens; P F Dodion; C Sanders; M Loos; N E Dethier; A R Delforge; P A Stryckmans; Y Kenis
Journal:  Eur J Cancer Clin Oncol       Date:  1987-08

3.  Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals.

Authors:  M C Bibby; J A Double; S A Ali; K C Fearon; R A Brennan; M J Tisdale
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

4.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

5.  Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512).

Authors:  L M Ching; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

6.  Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.

Authors:  J Plowman; V L Narayanan; D Dykes; E Szarvasi; P Briet; O C Yoder; K D Paull
Journal:  Cancer Treat Rep       Date:  1986-05

7.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin.

Authors:  H B Hewitt; E R Blake; A S Walder
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

8.  Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.

Authors:  J A Double; M C Bibby; P M Loadman
Journal:  Br J Cancer       Date:  1986-10       Impact factor: 7.640

9.  Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid).

Authors:  M C Bibby; J A Double; R M Phillips; P M Loadman
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

10.  Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA.

Authors:  I Parr; E Wheeler; P Alexander
Journal:  Br J Cancer       Date:  1973-05       Impact factor: 7.640

View more
  16 in total

1.  The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma.

Authors:  R C French; J Cummings; A MacLellan; J S MacPherson; A A Ritchie; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 2.  5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Authors:  Shufeng Zhou; Philip Kestell; Bruce C Baguley; James W Paxton
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

3.  Anticancer flavonoids are mouse-selective STING agonists.

Authors:  Sujeong Kim; Lingyin Li; Zoltan Maliga; Qian Yin; Hao Wu; Timothy J Mitchison
Journal:  ACS Chem Biol       Date:  2013-05-23       Impact factor: 5.100

Review 4.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

5.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.

Authors:  Kyle M Garland; Taylor L Sheehy; John T Wilson
Journal:  Chem Rev       Date:  2022-02-02       Impact factor: 60.622

7.  Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.

Authors:  K Henare; L Wang; L-C S Wang; L Thomsen; S Tijono; C-J J Chen; S Winkler; P R Dunbar; C Print; L-M Ching
Journal:  Br J Cancer       Date:  2012-03-13       Impact factor: 7.640

Review 8.  Nanodelivery of STING agonists against cancer and infectious diseases.

Authors:  Jiarong Zhou; Christian J Ventura; Ronnie H Fang; Liangfang Zhang
Journal:  Mol Aspects Med       Date:  2021-08-02

9.  Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Authors:  S M Tijono; K Guo; K Henare; B D Palmer; L-C S Wang; S M Albelda; L-M Ching
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

10.  Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies.

Authors:  S M O'Reilly; G J Rustin; K Farmer; M Burke; S Hill; J Denekamp
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.